Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Keros Therapeutics (KROS) Other Gross PP&E Adjustments (2019 - 2025)

Keros Therapeutics filings provide 7 years of Other Gross PP&E Adjustments readings, the most recent being -$15.8 million for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 19.6% to -$15.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$15.8 million, a 19.6% increase, with the full-year FY2025 number at -$15.8 million, up 19.6% from a year prior.
  • Other Gross PP&E Adjustments hit -$15.8 million in Q4 2025 for Keros Therapeutics, up from -$17.5 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $1.1 million in Q4 2021 to a low of -$20.3 million in Q4 2023.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$14.8 million (2024), compared with a mean of -$10.4 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: surged 96.47% in 2021 and later crashed 3405.37% in 2023.
  • Keros Therapeutics' Other Gross PP&E Adjustments stood at $1.1 million in 2021, then tumbled by 1196.59% to -$12.2 million in 2022, then tumbled by 65.96% to -$20.3 million in 2023, then rose by 3.21% to -$19.6 million in 2024, then rose by 19.6% to -$15.8 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$15.8 million (Q4 2025), -$17.5 million (Q3 2025), and -$18.1 million (Q2 2025) per Business Quant data.